Tarczoń Izabela, Jedynak-Wąsowicz Urszula, Lis Grzegorz, Tomasik Tomasz, Brzyski Piotr, Cichocka-Jarosz Ewa
"Przyladek Zdrowia", Krakow, Poland.
Department of Paediatrics, Jagiellonian University Medical College, Krakow, Poland.
Postepy Dermatol Alergol. 2021 Apr;38(2):235-243. doi: 10.5114/ada.2019.89715. Epub 2020 Feb 19.
Intramuscular adrenaline administration is the primary intervention in anaphylaxis.
To analyse the data on intervention in children admitted due to anaphylaxis to the tertiary paediatric centre and compare them to the data from the Network for Online-Registration of Anaphylaxis.
A validated structured on-line questionnaire was used to collect data concerning the first and second-line intervention in anaphylaxis. The study was conducted in cooperation with the European Anaphylaxis Registry.
The study group comprised 114 children (76 boys, 66.87%) aged 5 months-17 years with the predominance of moderate-to-severe anaphylaxis (grade III in Ring and Messmer's, and grade IV in Mueller's scale). In 103 (90.4%) children the first line of medical intervention was provided by medical staff. In the first-line intervention 39 (34.8%) children were given adrenaline. Five (4.4%) children were given the second dose of adrenaline and were admitted to the intensive care unit. In the second-line intervention adrenaline was given to 12 (15.6%) children. In one third it was at least the second reaction to the same trigger. Children treated with adrenaline were older (9.3 ±4.8 years), in comparison to those not treated (7.3 ±4.6 years, = 0.034). Directly after the episode of anaphylaxis the children got the prescription for the adrenaline autoinjector in 35.1%, emergency training in 7.9%, and counselling on the avoidance of the anaphylaxis trigger in 30.7%. Grade III R&M reaction increased 3-fold the odds of AAI prescription (95% CI: 1.08-8.15).
There is a strong need to continue education on proper management of anaphylaxis in children.
肌内注射肾上腺素是过敏性反应的主要干预措施。
分析因过敏性反应入住三级儿科中心的儿童的干预数据,并将其与过敏性反应在线注册网络的数据进行比较。
使用经过验证的结构化在线问卷收集有关过敏性反应一线和二线干预的数据。该研究是与欧洲过敏性反应登记处合作进行的。
研究组包括114名年龄在5个月至17岁之间的儿童(76名男孩,占66.87%),以中重度过敏性反应为主(Ring和Messmer分级为III级,Mueller分级为IV级)。103名(90.4%)儿童接受了医务人员的一线医疗干预。在一线干预中,39名(34.8%)儿童接受了肾上腺素治疗。5名(4.4%)儿童接受了第二剂肾上腺素并入住重症监护病房。在二线干预中,12名(15.6%)儿童接受了肾上腺素治疗。其中三分之一至少是对同一触发因素的第二次反应。接受肾上腺素治疗的儿童年龄较大(9.3±4.8岁),而未接受治疗的儿童年龄为(7.3±4.6岁,P=0.034)。过敏性反应发作后,直接给儿童开具肾上腺素自动注射器处方的占35.1%,进行急救培训的占7.9%,提供避免过敏性反应触发因素咨询的占30.7%。III级R&M反应使开具AAI处方的几率增加了3倍(95%CI:1.08-8.15)。
迫切需要继续开展关于儿童过敏性反应正确管理的教育。